Tissue Kallikrein Inhibitors Based on the Sunflower Trypsin Inhibitor Scaffold - A Potential Therapeutic Intervention for Skin Diseases.
Tissue kallikreins (KLKs), in particular KLK5, 7 and 14 are the major serine proteases in the skin responsible for skin shedding and activation of inflammatory cell signaling. In the normal skin, their activities are controlled by an endogenous protein protease inhibitor encoded by the SPINK5 gene. Loss-of-function mutations in SPINK5 leads to enhanced skin kallikrein activities and cause the skin disease Netherton Syndrome (NS). We have been developing inhibitors based on the Sunflower Trypsin Inhibitor 1 (SFTI-1) scaffold, a 14 amino acids head-to-tail bicyclic peptide with a disulfide bond. To optimize a previously reported SFTI-1 analogue (I10H), we made five analogues with additional substitutions, two of which showed improved inhibition. We then combined those substitutions and discovered a variant (Analogue 6) that displayed dual inhibition of KLK5 (tryptic) and KLK7 (chymotryptic). Analogue 6 attained a tenfold increase in KLK5 inhibition potency with an Isothermal Titration Calorimetry (ITC) Kd of 20nM. Furthermore, it selectively inhibits KLK5 and KLK14 over seven other serine proteases. Its biological function was ascertained by full suppression of KLK5-induced Protease-Activated Receptor 2 (PAR-2) dependent intracellular calcium mobilization and postponement of Interleukin-8 (IL-8) secretion in cell model. Moreover, Analogue 6 permeates through the cornified layer of in vitro organotypic skin equivalent culture and inhibits protease activities therein, providing a potential drug lead for the treatment of NS.
Infection, Immunity and Inflammation Programme, Immunobiology Section, UCL GOS Institute of Child Health, London, United Kingdom.
Wenjie
W
Chen
Genetics and Genomic Medicine Programme, UCL GOS Institute of Child Health, London, United Kingdom.
Veronica A
VA
Kinsler
Department of Chemistry, University College London, London, United Kingdom.
Derek
D
Macmillan
Infection, Immunity and Inflammation Programme, Immunobiology Section, UCL GOS Institute of Child Health, London, United Kingdom.
Wei-Li
WL
Di
D002460:Cell Line; D006368:Helianthus / Q000378:metabolism*; D006801:Humans; D016209:Interleukin-8 / Q000378:metabolism; D056770:Netherton Syndrome / Q000188:drug therapy / Q000378:metabolism; D010456:Peptides, Cyclic / Q000037:antagonists & inhibitors* / Q000378:metabolism; D053491:Proteinase Inhibitory Proteins, Secretory / Q000494:pharmacology; D044464:Receptor, PAR-2 / Q000378:metabolism; D012867:Skin / Q000187:drug effects / Q000378:metabolism; D012871:Skin Diseases / Q000188:drug therapy* / Q000378:metabolism; D020840:Tissue Kallikreins / Q000037:antagonists & inhibitors*; D014361:Trypsin Inhibitors / Q000494:pharmacology
D016209:Interleukin-8; D010456:Peptides, Cyclic; D053491:Proteinase Inhibitory Proteins, Secretory; D044464:Receptor, PAR-2; C448501:SFTI-1 peptide, sunflower; D014361:Trypsin Inhibitors; D020840:Tissue Kallikreins